

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

**ANTIBACTERIAL FREE FATTY ACIDS: ACTIVITIES,  
MECHANISMS OF ACTION AND  
BIOTECHNOLOGICAL POTENTIAL**

**Andrew P. Desbois<sup>1</sup> and Valerie J. Smith<sup>2\*</sup>**

**<sup>1</sup>Biomedical Sciences Research Complex, School of Biology, University of St  
Andrews, Fife, KY16 9ST, UK**

**<sup>2</sup>Scottish Oceans Institute (formerly Gatty Marine Laboratory), University of St  
Andrews, Fife, KY16 8LB, UK**

\*Author for correspondence: email [vjs1@st-andrews.ac.uk](mailto:vjs1@st-andrews.ac.uk); phone +44 (1334)  
463474; fax +44 (1334) 463443.

**Running title: ANTIBACTERIAL FREE FATTY ACIDS**

1 **Abstract**

2

3 Amongst the diverse and potent biological activities of free fatty acids (FFAs) is the  
4 ability to kill or inhibit the growth of bacteria. The antibacterial properties of FFAs  
5 are used by many organisms to defend against parasitic or pathogenic bacteria. Whilst  
6 their antibacterial mode of action is still poorly understood, the prime target of FFA  
7 action is the cell membrane. Here, FFAs disrupt the electron transport chain and  
8 oxidative phosphorylation. Besides interfering with cellular energy production, FFA  
9 action may also result from the inhibition of enzyme activity, impairment of nutrient  
10 uptake, generation of toxic peroxidation and auto-oxidation degradation products or  
11 direct lysis of bacterial cells. Their broad spectrum of activity, non-specific mode of  
12 action and safety makes them attractive as antibacterial agents for various applications  
13 in medicine, agriculture and food preservation, especially where the use of  
14 conventional antibiotics is undesirable or prohibited. Moreover, the evolution of  
15 inducible FFA-resistant phenotypes is less problematic than with conventional  
16 antibiotics. The potential for commercial or biomedical exploitation of antibacterial  
17 FFAs, especially for those from natural sources, is discussed.

18

19 **Keywords:** antibiotic; antimicrobial; drug resistance; lipid; natural products.

20

21 **1. Introduction**

22

23 Fatty acids (FAs) are ubiquitous molecules typically found bound to other compounds  
24 such as glycerol, sugars or phosphate headgroups to form lipids. Lipids are integral  
25 components of cell structures, e.g. membranes, which are made up of phospholipids,

1 and energy stores that are often composed of triglycerides. FAs can be released from  
2 lipids, typically by enzyme action, to become free fatty acids (FFAs), which have  
3 diverse and potent biological activities (Table 1).

4

5 FFAs consist of a chain of carbon atoms attached to hydrogen atoms (Figure 1). The  
6 number of carbon atoms varies but those in biological systems usually have an even  
7 number between 10 and 28 and this review mainly concentrates on these. At one end  
8 of the carbon chain is a carboxyl group ( $-\text{COOH}$ ) and at the other end is a methyl  
9 group ( $-\text{CH}_3$ ) (Figure 1). The carboxyl group is hydrophilic and ionised when  
10 solubilised in water whereas the carbon chain is hydrophobic, making the entire  
11 molecule amphipathic. FAs with  $<8$  carbon atoms are considered short-chain whereas  
12 those with  $>16$  carbon atoms are regarded as long-chain. Unsaturated FAs have one or  
13 more  $\text{C}=\text{C}$  double bonds in the carbon chain while the carbon atoms in saturated FAs  
14 are all joined by  $\text{C}-\text{C}$  single bonds (Figure 1). Lipases (the group of lipolytic enzymes  
15 that cleave FAs from lipid headgroups by hydrolysis to give FFAs) can be specific for  
16 certain types of lipid but they may also discriminate the FAs that they cleave on their  
17 position on the lipid headgroup and the length and unsaturation of the FA's carbon  
18 chain.

19

20 The biological activities of FFAs have roles in host defences against potential  
21 pathogenic or opportunistic micro-organisms. An important aspect of this is growth  
22 inhibition or the direct killing of bacteria. There is now an extensive literature  
23 concerning the antibacterial effects of various FFAs from a wide range of biological  
24 sources, including algae, animals and plants (McGaw et al. 2002; Wille and  
25 Kydonieus 2003; Desbois et al. 2008, 2009). Indeed, FFAs are often identified as the

1 active ingredients in ethnic and herbal medicines (Yff et al. 2002; McGaw et al.  
2 2002). This review aims to summarise some of this work and to discuss the various  
3 mechanisms and structural features of FFAs that causes them to prevent bacterial  
4 growth or survival. Furthermore, the potential for commercial or biomedical  
5 exploitation of antibacterial FFAs is discussed.

6

## 7 **2. Free fatty acids in antibacterial defence**

8

9 The antibacterial effects of FFAs are frequently observed during bioassay-guided  
10 fractionation of extracts from a variety of organisms (Hemsworth and Kochan 1978;  
11 McGaw et al. 2002; Wille and Kydonieus 2003; Desbois et al. 2009). The  
12 antibacterial actions of FFAs are typically broad spectrum and of potencies  
13 comparable to natural antimicrobial peptides (AMPs) *in vitro* (Georgel et al. 2005).  
14 FFAs function in the antimicrobial defences of many multicellular organisms,  
15 including mammals (Hemsworth and Kochan 1978; Georgel et al. 2005), plants  
16 (Weber 2002), molluscs (Benkendorff et al. 2005), seaweeds (Küpper et al. 2006) and  
17 amphibians (Rickrode 1986). Whilst FFAs are not as structurally diverse as the more  
18 widely studied AMPs their importance in the human innate immune system is well  
19 established, particularly in the defence of skin and mucosal surfaces (Thormar and  
20 Hilmarsson 2007; Drake et al. 2008). Indeed, FFAs are the most active antimicrobial  
21 agents present in human skin lipid samples (Wille and Kydonieus 2003). There is 10-  
22 15 µg of FFAs per square centimetre on human skin, of which lauric acid (C12:0),  
23 myristic acid (C14:0), palmitic acid (C16:0), sapienic acid (C16:1n-10) and *cis*-8-  
24 octadecenoic acid (C18:1n-10) are the most abundant (Wille and Kydonieus 2003;  
25 Takigawa et al. 2005). FFAs are produced on the skin by lipolytic cleavage of lipids

1 secreted from the sebaceous glands (Shalita 1974; Fluhr et al. 2001; Drake et al. 2008)  
2 and their presence on the skin is sufficient to control the bacterial microbiota  
3 (Takigawa et al. 2005; Georgel et al. 2005; Kenny et al. 2009). The most important  
4 antibacterial FFA in human skin exudate is C16:1n-10, a long-chain monounsaturated  
5 FFA, and skin deficient in this and other FFAs tends to be more susceptible to  
6 colonisation by the opportunistic pathogen, *Staphylococcus aureus* (Takigawa et al  
7 2005; Georgel et al. 2005). However, if the skin is treated with C16:1n-10 protection  
8 against colonisation is bolstered (Takigawa et al 2005; Georgel et al. 2005). Besides  
9 inhibiting or killing bacteria directly, FFAs also make conditions unfavourable for the  
10 growth of certain bacteria on the skin surface by maintaining an acidic pH (Fluhr et al.  
11 2001; Takigawa et al. 2005). FFAs may further affect the expression of bacterial  
12 virulence factors (Table 1), which are important or essential for the establishment of  
13 an infection, probably by disrupting cell-to-cell signalling. Thus, saturated and  
14 unsaturated FFAs can prevent initial bacterial adhesion and subsequent biofilm  
15 formation (Kurihara et al 1999; Osawa et al 2001; Kankaanpää et al. 2004; Won et al  
16 2007; Stenz et al. 2008; Davies and Marques 2009). Moreover, the swarming  
17 behaviour of the urinary tract pathogen, *Proteus mirabilis*, is inhibited by medium-  
18 and long-chain saturated FFAs (Liaw et al. 2004). The expression of certain toxins,  
19 haemolysins and enzymes conferring drug resistance are all down-regulated in the  
20 presence of various saturated and unsaturated FFAs (Ruzin and Novick 2000; Liaw et  
21 al. 2004; Clarke et al 2007) while genes responsible for iron uptake and extracellular  
22 proteases can be similarly reduced (Kenny et al 2009). The ability of various species  
23 of bacteria to resist the action of FFAs and subvert these epithelial defences certainly  
24 explains, at least in part, the success of certain skin and mucosal pathogens (Clarke et  
25 al. 2007; Drake et al. 2008).

1  
2 Perhaps less well known is the role that FFAs play in the defence of single-celled  
3 eukaryotic organisms against bacterial threats. In microbial eukaryotes, such as  
4 microalgae, FAs are found primarily in the lipids that constitute the cell membranes  
5 and energy storage structures but during cellular disintegration large quantities of  
6 FFAs are released from cellular lipids by host lipolytic enzymes (Jüttner 2001;  
7 Wichard et al. 2007). A high proportion of the FFAs that are freed from the cell  
8 membranes, including those around the photosynthetic plastid, are mono- and  
9 polyunsaturated varieties (Cutignano et al. 2006). These FFAs are toxic to  
10 invertebrate grazers, which may have caused the microalgal cell to lose its integrity in  
11 the first instance (Jüttner 2001; Wichard et al. 2007). Therefore, the toxic FFAs act to  
12 reduce grazer numbers and ultimately grazing pressure (Jüttner 2001). At first it might  
13 seem counter-intuitive that this defence strategy requires the host cell to undergo  
14 mechanical damage and death but in evolutionary terms it has benefits because  
15 neighbouring microalgal cells, particularly in biofilms, would be expected to be  
16 clones or very closely related. That these same FFAs are potently antimicrobial means  
17 similar protection may be afforded to microalgae under threat from pathogenic  
18 bacteria or viruses. Whilst the initial host will not survive, FFAs released from a  
19 microalgal cell that has been damaged by a pathogen will act on pathogens in the local  
20 vicinity reducing their numbers, therefore conferring some protection of its  
21 neighbouring relatives from onward transmission. This ‘population level’ defence  
22 may be considered metabolically inexpensive as the FFAs form essential cellular  
23 components with the lipases already synthesised and present within the cell to carry  
24 out vital processes.

25

### 1 **3. Antibacterial activity and FFA structure**

2  
3 The antibacterial activity of each FFA is influenced by its structure and shape. This, in  
4 turn, is a function of the length of the carbon chain and the presence, number, position  
5 and orientation of double bonds (Figure 2). The literature contains contrasting reports  
6 concerning the relationship between a FFA's structure and its antibacterial activity but  
7 some general trends do emerge. The –OH group of the carboxyl group seems to be  
8 important for the antibacterial activity of FFAs as methylated FFAs (Figure 1) often  
9 have reduced or no activity (Kodicek and Worden 1945; Zheng et al. 2005).

10  
11 Medium- and long-chain unsaturated FFAs tend to be more active against Gram-  
12 positive bacteria than Gram-negatives (Kodicek and Worden 1945; Galbraith et al.  
13 1971). In general, unsaturated FFAs tend to have greater potency than saturated FFAs  
14 with the same length carbon chain (Kabara et al. 1972; Greenway and Dyke 1979;  
15 Feldlaufer et al. 1993; Zheng et al. 2005; Desbois et al. 2008). Within series of  
16 monounsaturated FFAs, the most potent usually have 14 or 16 carbon atoms (Kabara  
17 et al. 1972; Feldlaufer et al. 1993). Often a direct correlation exists between the  
18 number of double bonds in an unsaturated FFA's carbon chain and its antibacterial  
19 efficacy (Saito et al. 1984; Knapp and Melly 1986; Feldlaufer et al. 1993). The double  
20 bonds in naturally occurring FFAs typically have *cis* orientation and these tend to  
21 have greater antibacterial activity than FFAs with double bonds in *trans* orientation  
22 (Galbraith et al. 1971; Kabara et al. 1972; Feldlaufer et al. 1993), probably because  
23 the structures of *trans*-bonded unsaturated FFAs resemble saturated FFAs (Figure 2).  
24 Whilst only a few studies have investigated the effect of bond position in the carbon  
25 chain of FFAs there is some evidence that the position of double bonds can affect

1 potency and spectrum of antibacterial action (Kabara et al. 1977; Feldlaufer et al.  
2 1993; Wille and Kydonieus 2003).  
3  
4 For saturated FFAs, the most active have 10 or 12 carbons in the chain and  
5 antibacterial efficacy tends to decrease, as the chain length gets longer or shorter  
6 (Galbraith et al. 1971; Kabara et al. 1972; Bergsson et al. 2001; Sun et al. 2003; Wille  
7 and Kydonieus 2003). However, others workers have reported that FFAs with 14, 16  
8 or 18 carbon atoms can be more potent than FFAs with 10 or 12 carbons against  
9 certain species of bacteria (Willett and Morse 1966; Galbraith and Miller 1973a;  
10 Miller et al. 1977). Comparisons between studies are complicated because different  
11 authors have used a variety of methodological approaches to determine and measure  
12 potency with considerable variation in the inoculum and incubation conditions.  
13 Moreover, the relative activity of FFAs may depend on whether a complete growth  
14 inhibition assay or an  $IC_{50}$  determination is used (Willett and Morse 1966). To enable  
15 simple comparison, ideally all determinations of minimum inhibitory concentration  
16 (MIC) and minimum bactericidal concentration (MBC) for FFAs need to adhere to  
17 standardised definitions and protocols such as those published by the Clinical and  
18 Laboratory Standards Institute (CLSI) (CLSI, 2000).

19

#### 20 **4. Mechanisms of antibacterial activity**

21

22 It remains unclear exactly how FFAs exert their antibacterial activities but the prime  
23 target seems to be the bacterial cell membrane and the various essential processes that  
24 occur within and at the membrane (Figure 3). Some of the detrimental effects on  
25 bacterial cells can be attributed to the detergent properties of FFAs on account of their

1 amphipathic structures. This allows them to interact with the cell membrane to create  
2 transient or permanent pores of variable size. At higher concentrations detergents,  
3 such as FFAs, can solubilise the membrane to such an extent that various membrane  
4 proteins or larger sections of the lipid bilayer are released. The key membrane-located  
5 process affected by FFAs is the production of energy caused by interference with the  
6 electron transport chain and the disruption of oxidative phosphorylation (Sheu and  
7 Freese 1972; Galbraith and Miller 1973b; Miller et al. 1977; Boyaval et al. 1995;  
8 Wojtczak and Więckowski 1999). Other processes that may contribute to bacterial  
9 growth inhibition or death include: cell lysis, inhibition of enzyme activity,  
10 impairment of nutrient uptake and the generation of toxic peroxidation and auto-  
11 oxidation products (Figure 3). FFAs can kill a bacterium outright (bactericidal action)  
12 or inhibit its growth (bacteriostatic action), which is reversible and means that the  
13 bacterium remains viable but cannot undergo cell division in the presence of the FFA  
14 (Kodicek and Worden 1945; Sheu and Freese 1972). Assays used to investigate the  
15 antibacterial activities of FFAs do not always discriminate between bactericidal and  
16 bacteriostatic actions but it is reasonable to assume that growth inhibition cannot  
17 continue indefinitely and eventually a growth-inhibited bacterium will die. In  
18 describing the processes of antibacterial activity below, little distinction is made as to  
19 whether the outcome is bactericidal or bacteriostatic.

20

#### 21 *4.1 Disruption of electron transport chain*

22 The inner membrane of Gram-positive and Gram-negative bacteria is an important  
23 site for energy production and it is where the electron transport chain is located. The  
24 various carriers in the electron transport chain, which are embedded within the  
25 membrane, pass electrons from one carrier to another until two electrons combine

1 with the final acceptor, usually oxygen, and two protons to form water (Mitchell  
2 1961). During this process protons are exported from the inside of the cell whilst the  
3 concentration of electrons in the cytosol increases. This generates a proton gradient  
4 and membrane potential which are crucial for the production of ATP by the enzyme,  
5 ATP synthase (Mitchell 1961). Medium- and long-chain saturated and unsaturated  
6 FFAs that gain access through the cell wall or outer membrane of a bacterium, can  
7 perhaps bind to the carriers of the electron transport chain directly or insert into the  
8 inner membrane causing the electron carriers to move apart or be displaced from the  
9 membrane entirely (Galbraith and Miller 1973b; Peters and Chin 2003). In each case  
10 the ability of the electron transport chain to transfer electrons is impaired so that the  
11 proton gradient and membrane potential are reduced. This results in a reduction in  
12 ATP production and the bacterium becomes deprived of an essential source of energy.  
13 Both unsaturated and saturated FFAs could translocate or bind the electron carriers  
14 directly but complete displacement from the membrane is likely achieved by  
15 unsaturated FFAs only, probably because they increase membrane fluidity (Greenway  
16 and Dyke 1979; Chamberlain et al. 1991; Stulnig et al. 2001). This is because the *cis*-  
17 bonds in unsaturated FAs cause a kink in the carbon chain (Figure 2) that prevents  
18 these FAs from packing tightly in the membrane. Thus, when medium- and long-  
19 chain unsaturated FFAs are incorporated into the membrane there is an increase in  
20 fluidity that can develop into membrane instability (Chamberlain et al. 1991; Stulnig  
21 et al. 2001). Conversely, medium- and long-chain saturated FFAs (and *trans*-bonded  
22 unsaturated FFAs) that lack a kinked structure can be packed more tightly (Figure 2).  
23 Hence, medium- and long-chain saturated FFAs can reduce membrane fluidity and  
24 disrupt electron transport perhaps by restricting the movement of carriers within the  
25 membrane (Sheu and Freese 1972). Moreover, as explained above, solubilisation of

1 the membrane by the detergent effect of FFAs could also account for the loss of vital  
2 components of the electron transport chain from the membrane.

3

#### 4 *4.2. Uncoupling of oxidative phosphorylation*

5 FFAs may further prevent energy production by uncoupling oxidative  
6 phosphorylation. Thus the potential energy created by the electron transport chain  
7 dissipates as heat rather than being used for ATP synthesis (Sheu and Freese 1972;  
8 Greenway and Dyke 1979; Beck et al. 2007). ATP synthase (also located on the  
9 bacterial inner membrane) uses the energy from the proton motive force, which results  
10 from the proton gradient and membrane potential, created by the electron transport  
11 chain, to convert ADP to ATP. Interaction of FFAs with the bacterial inner membrane  
12 can affect this process and reduce or prevent the production of ATP (Sheu and Freese  
13 1972; Galbraith and Miller 1973b). A simple way this could happen is for a saturated  
14 or unsaturated FFA to bind directly to ATP synthase itself, which could prevent the  
15 enzyme functioning correctly. Alternatively, FFAs can interfere with the proton  
16 gradient and membrane potential. This weakens the proton motive force upon which  
17 ATP synthesis relies. FFAs, particularly unsaturated ones, can reduce ATP synthesis  
18 by increasing the permeability of the membrane to protons (Borst et al. 1962; Boyaval  
19 et al. 1995). This could happen anywhere on the inner membrane or at specific proton  
20 pores, such as those already identified in mitochondria (Więckowski and Wojtczak  
21 1998; Wojtczak and Więckowski 1999; Beck et al. 2007). Thus protons enter the  
22 cytosol causing a reduction in the proton gradient and membrane potential. Moreover,  
23 the enzyme's ability to synthesise ATP is further diminished because the protons  
24 bypass ATP synthase (Boyaval et al. 1995; Więckowski and Wojtczak 1998). The  
25 proton gradient and membrane potential are also thought to be reduced by FFAs

1 entering the cytosol, dissociating the proton from its carboxyl group and then  
2 returning across the membrane to the exterior thus increasing the cytosolic  
3 concentration of protons (Wojtczak and Więckowski 1999; Beck et al. 2007;  
4 Schönfeld and Wojtczak 2008).

5

#### 6 *4.3 Cell lysis*

7 Due to their structure, the insertion of unsaturated FFAs into the bacterial inner  
8 membrane causes it to become more fluid and permeable (Greenway and Dyke 1979;  
9 Chamberlain et al. 1991). The increased permeability of the membrane by the  
10 insertion of unsaturated medium- and long-chain FFAs can allow internal contents to  
11 leak from the cell, which can cause growth inhibition or even death (Galbraith and  
12 Miller 1973a; Greenway and Dyke 1979; Speert et al. 1979; Wang and Johnson 1992;  
13 Boyaval et al. 1995; Shin et al. 2007). If membrane fluidity increases excessively the  
14 membrane can become unstable and the cell will ultimately lyse (Carson and Daneo-  
15 Moore 1980). Indeed, unsaturated FFAs have been shown to lyse single-celled algae  
16 (Wu et al. 2006), bacteria (Carson and Daneo-Moore 1980; Wang and Johnson 1992;  
17 Thompson et al. 1994; Shin et al. 2007), erythrocytes (Fu et al. 2004), mammalian  
18 cells such as sheep fibroblasts (Thormar et al. 1987) and vero cells (Thormar et al.  
19 1987), or even enveloped viruses (Thormar et al. 1987). Aside from increased  
20 membrane fluidity the detergent effect of FFAs, which at high concentrations may  
21 solubilise large sections of the cell membrane, could further account for complete cell  
22 lysis. In addition, saturated FFAs can induce autolysis of bacterial cell walls in some  
23 species, perhaps triggered by a reduction in membrane fluidity (Tsuchido et al. 1985;  
24 Cybulski et al. 2002; Kenny et al. 2009).

25

1 *4.4. Inhibition of enzyme activity*

2 FFAs are potent inhibitors of diverse enzymes and unsaturated FFAs usually have  
3 greater inhibitory activity than saturated ones (Kurihara et al. 1999; Zheng et al. 2005;  
4 Won et al. 2007; Hamel 2009; Sado-Kamdem et al. 2009). Inhibition of enzymes in  
5 the membrane or cytosol that are crucial for bacterial survival and growth could  
6 account for some of the antibacterial effects of FFAs. Interestingly, Zheng et al.  
7 (2005) showed that unsaturated FFAs can inhibit bacterial fatty acid biosynthesis *in*  
8 *vivo*, which will, in turn, affect the composition of the bacterial cell membrane. This  
9 could cause altered and inappropriate cell membrane fluidity and permeability leading  
10 to the membrane-related problems described above.

11  
12 *4.5. Impairment of nutrient uptake*

13 Saturated and unsaturated FFAs can inhibit the ability of bacteria to take up nutrients,  
14 such as amino acids, thereby effectively starving the bacterium of the nutrients it  
15 requires to remain viable (Galbraith and Miller 1973b; Shibasaki and Kato 1978). It is  
16 not clear whether FFAs reduce nutrient uptake by directly disrupting the membrane-  
17 located transporter proteins (by direct binding or complete displacement) or whether it  
18 is a consequence of the reduced proton motive force required for the energy-requiring  
19 process of active transport.

20  
21 *4.6 Peroxidation and auto-oxidation*

22 Other workers have suggested that it is the action of secondary degradation products  
23 of FFAs that are responsible for their antibacterial activities. These could be produced  
24 by peroxidation that yields H<sub>2</sub>O<sub>2</sub> and reactive oxygen species (Knapp and Melly 1986;  
25 Hazell and Graham 1990; Wang and Johnson 1992; Schönfeld and Wojtczak 2008) or

1 auto-oxidation of unsaturated FFAs that creates oxylipins and short-chain aldehydes,  
2 which are antibacterial in their own right (Gutteridge et al. 1974; Adolph et al. 2004).

3

4 Of course, the specific mechanisms by which individual FFAs cause bacterial growth  
5 inhibition and/or death will depend on fatty acid structure, the target bacterium and  
6 the sites that the FFA can access. Effective control of bacterial growth and survival  
7 might involve multiple mechanisms, each of which might, directly or indirectly, be  
8 affected by factors such as pH and temperature (Galbraith and Miller 1973c; Kabara  
9 et al. 1977; Miller et al. 1977; Shibasaki and Kato 1978; Greenway and Dyke 1979;  
10 Wang and Johnson 1992; Sun et al. 2003). Often it is not clear whether changes in  
11 antibacterial activity caused by different pH and temperature conditions is due to  
12 alterations in the solubility of the FFA or whether these conditions have greater  
13 influence on the physiology, and therefore the susceptibility, of the target bacterium.

14

## 15 **5. Bacterial resistance to killing by FFAs**

16

17 Some bacterial species are naturally resistant to the antibacterial action of FFAs. The  
18 cell walls of Gram-positive bacteria and the outer cell membranes of Gram-negative  
19 species protect against FFAs, as once these structures are removed the cells are more  
20 susceptible (Galbraith and Miller 1973a; Miller et al. 1977). Differential susceptibility  
21 of bacterial species to the action of FFAs is likely to be due to the FFA's ability to  
22 permeate the outer membrane or cell wall, which will enable access to the sites of  
23 action on the inner membrane. Interestingly, *S. aureus* appears to up-regulate the  
24 expression of genes encoding proteins involved in the synthesis of the cell wall upon  
25 exposure to unsaturated FFAs; a strategy that no doubt serves as a protective measure

1 because a thicker cell wall makes it more difficult for FFAs to penetrate and exert  
2 their antibacterial effects at the cell membrane (Kenny et al. 2009). Furthermore,  
3 additional wall material makes the cell surface more highly charged and thus less  
4 hydrophobic. Therefore FFAs are less attracted to the cell and are less likely to insert  
5 into the inner membrane (Clarke et al., 2007; Kenny et al. 2009). The ability of some  
6 bacteria to change their cell surface hydrophobicity (Clarke et al., 2007; Kenny et al.  
7 2009) may explain why certain strains of the same species differ with respect to their  
8 susceptibility to the antibacterial effects of FFAs (e.g. Heczko et al. 1979; Ko et al.  
9 1978; Lacey and Lord 1981; Kenny et al. 2009).

10

11 Another factor that might contribute to the resistance of some bacterial strains to  
12 disruption by FFA is the presence of membrane-located carotenoids. Carotenoids are  
13 antioxidants that also stabilise the cell membrane by decreasing its fluidity. Thus their  
14 presence may counteract the effects of reactive FFA degradation products or FFA-  
15 induced increases in membrane fluidity (Chamberlain et al. 1991). Indeed, strains of  
16 *S. aureus* containing high levels of carotenoids are less susceptible to the antibacterial  
17 effects of unsaturated FFAs than strains with lower quantities of carotenoids in their  
18 membranes (Chamberlain et al. 1991; Xiong and Kapral 1992). Further work is  
19 necessary to ascertain whether similar differences in the presence of carotenoids, or  
20 other membrane-stabilising sterols, account for the variation in FFA susceptibility  
21 between different strains of other bacterial species. Certainly there is a need to better  
22 elucidate the precise mechanism(s) of antibacterial action by FFAs in order to  
23 understand how certain bacteria evade or abrogate their bactericidal effects.

24

## 25 **5. Uses and applications of antibacterial free fatty acids**

1

2 The broad spectrum of activity and non-specific mode of action of at least some FFAs  
3 make them attractive as antibacterial agents for various applications in medicine,  
4 agriculture, food preservation and the formulation of cosmetics or nutraceuticals,  
5 especially where the use of conventional antibiotics is undesirable or forbidden. Many  
6 FFAs are plentiful in natural sources, non-toxic (Kabara 1979) and ‘generally  
7 regarded as safe’ (U.S. Food and Drug Administration 2007). By and large, the  
8 evolution of inducible FFA-resistant phenotypes is less problematic than with  
9 conventional antibiotics (Lacey and Lord 1981; Petschow et al. 1996; Sun et al.  
10 2003). Kenny et al. (2009) screened 5000 transposon mutants of *S. aureus* for FFA-  
11 resistance but found none and, in fact, most mutants were even more susceptible to  
12 FFA action. Yet despite their obvious potential, the antibacterial properties of FFAs  
13 have still to be fully exploited. One reason may be because some FFAs, particularly  
14 long-chain polyunsaturated ones, can be unstable (Kodicek and Worden 1945;  
15 Gutteridge et al. 1974; Guil-Guerrero et al. 2001) and tend to bind non-specifically to  
16 proteins or other compounds (Kodicek and Worden 1945; Galbraith et al. 1971; Lacey  
17 and Lord 1981; Boyaval et al. 1995; Petschow et al. 1996). A further problem may be  
18 the perceived lack of patentable intellectual property concerning these ubiquitous  
19 antibacterial compounds. However, these problems can be overcome and the  
20 usefulness of FFAs in antibacterial applications should not be dismissed.

21

### 22 *5.1 Biomedical therapeutics*

23 FFAs are defence molecules in the innate immune systems of multicellular organisms  
24 that could be manipulated for the prevention and treatment of bacterial diseases. The  
25 increasing prevalence of drug-resistant bacteria as well as an enhanced appreciation

1 for the mechanisms of drug-resistance acquisition is necessitating the discovery and  
2 development of alternative anti-infectives to conventional antibiotics (Thormar and  
3 Hilmarsson 2007). The future exploitation of particular FFAs for systemic treatment  
4 may be limited by their toxicity at high doses to certain eukaryotic cells (Table 1),  
5 although Clarke et al. (2007) successfully used C16:1n-10 to treat systemic *S. aureus*  
6 infections in mice. At present, the best prospects for exploitation in medicine are for  
7 therapies aimed at enhancing the concentrations of natural FFAs on the skin.

8  
9 Topical antibacterial decolonising agents are given to patients intra-nasally before  
10 surgery to disinfect the nose and reduce the chances of contracting a post-surgical  
11 infection (van Rijen et al. 2008). Presently, the antibiotic of choice for this is  
12 mupirocin but resistance to this agent is becoming increasingly prevalent and  
13 treatment failure is now more common (Simor et al. 2007). Linolenic acid (C18:3) can  
14 reduce *S. aureus* numbers on human skin and therefore could be exploited as an  
15 alternative to mupirocin (Lacey and Lord 1981). Furthermore, Lukowski et al. (2008)  
16 have shown that emulsions of fatty acid-rich extracts from microalgae can reduce  
17 MRSA attachment to pre-treated skin. Thus, there is potential for the development of  
18 a gel containing one or more FFAs with potent activity for Gram-positive pathogens,  
19 such as MRSA, to prevent and reduce bacterial colonisation of the skin and nose.

20  
21 As far as sexual health is concerned there are also possibilities for a FFA-containing  
22 product to reduce the transmission of sexually transmitted infections (STIs),  
23 especially those caused by *Neisseria gonorrhoeae* (Bergsson et al. 1999; Thormar et  
24 al. 1999), *Chlamydia trachomatis* (Bergsson et al. 1998; Thormar et al. 1999) or  
25 herpes simplex virus (Kristmundsdóttir et al 1999). Indeed, formulations containing

1 monoglycerides (single FAs bound to glycerol) have demonstrable efficacy against  
2 STIs *in vivo* (Neyts et al. 2000). Other potential therapeutic applications suggested for  
3 FFAs in humans might be in the prevention of dental caries (Kurihara et al. 1999;  
4 Osawa et al. 2001; Won et al. 2007), in reducing the incidence of infant  
5 gastrointestinal infections by adding to formula milk (Thormar et al. 1987; Isaacs et  
6 al. 1995), in the treatment of acne (Nakatsuji et al 2009; Yang et al 2009), or in the  
7 treatment of stomach ulcers caused by *Helicobacter pylori* (Hazell and Graham 1990;  
8 Thompson et al. 1994; Petschow et al. 1996).

9

## 10 5.2 Agriculture and aquaculture

11 Antibiotics are used as animal feed supplements to increase the production of meat or  
12 cultured fish, as they reduce bacterial abundance in the digestive system resulting in  
13 more energy being diverted to weight accumulation (food conversion) (Dibner and  
14 Richards 2005). However, concerns about antibiotic resistance transferring to human  
15 pathogens and anxiety about antibiotic residues and environmental contamination  
16 (Smith et al. 2002) has led to the ban on the use of conventional antibiotics in  
17 livestock foodstuffs in the European Union (European Union, 2005) and similar bans  
18 are being considered elsewhere (Dibner and Richards 2005). Therefore, opportunities  
19 exist to replace these conventional antimicrobial agents and FFAs may be a realistic  
20 alternative. Moreover, as FFAs are also active against methane producing Archaea  
21 (methanogens) in the guts of ruminants they could reduce emissions of this important  
22 greenhouse gas (Ungerfeld et al. 2005).

23

24 Piglets treated with a source of lipids and a lipolytic enzyme to release antibacterial  
25 FFAs in the animals' guts show a reduction in the abundance of gut microbiota and

1 improved weight gain and feed conversion (Dierick et al. 2002). However, at present,  
2 the high cost of the lipid component remains the stumbling block to implementation  
3 (Dierick et al. 2002). Here, we suggest that single-celled algae could be an  
4 inexpensive source of FFAs. These micro-organisms are autotrophic, negating the  
5 need for costly heterotrophic sources of carbon, can be cultured on non-arable land in  
6 salt water and can achieve growth rates similar to bacteria (de la Noue and De Pauw  
7 1988). Moreover, technologies in the culture, harvest and manipulation of single-  
8 celled algae for their lipids are established but continue to improve, particularly due to  
9 recent interest in biofuels (Chisti 2008). Single-celled algal species can be selected  
10 and their lipid composition further manipulated to enrich for the particular mixture of  
11 FFAs required (Borowitzka 1988). The algae, which are a nutrient source in  
12 themselves, typically also contain various health promoting vitamins and antioxidants  
13 (de la Noue and De Pauw 1988), could be incorporated into animal feed. The addition  
14 of exogenous lipolytic enzymes may be unnecessary for certain algal species as the  
15 cells contain their own enzymes activated on cell disintegration (Jüttner 2001;  
16 Wichard et al. 2007).

17

18 FFAs added to feed may also increase survival in commercial rabbit farms where  
19 losses to enteric diseases can be high. Rabbits experimentally infected with  
20 pathogenic *Escherichia coli* have a better chance of survival if the feed is  
21 supplemented with caprylic acid in its free form or as triglycerides (Skřivanová et al.  
22 2008). These rabbits also have significantly fewer *E. coli* in their faeces and stomachs  
23 compared to rabbits fed a non-supplemented diet (Skřivanová et al. 2008). Emulsions  
24 of monoglycerides can reduce the burden of pathogenic bacteria, such as  
25 *Campylobacter jejuni*, in chicken feed (Thormar et al. 2006). A similar approach

1 could be used for the prevention of disease in aquaculture and mariculture, as FFAs  
2 are active against industry-relevant bacterial pathogens (Benkendorff et al. 2005;  
3 Desbois et al. 2009) and pose virtually no environmental harm from leaching into the  
4 water. Finally, antibacterial FFAs have also been considered in the treatment of  
5 bovine mastitis (Hogan et al. 1987; Nair et al. 2005) and in the control of honeybee  
6 infections (Feldlaufer et al. 1993; Hornitzky 2003).

7

## 8 **6. Discussion and concluding remarks**

9

10 As discussed above, the antibacterial properties of FFAs are well recognised and  
11 because they act through different mechanisms to most conventional antibiotics they  
12 offer potential for commercial exploitation. However, there are a few problems that  
13 have hindered progress thus far. First, some FFAs have an unpleasant taste (Stephan  
14 and Steinhart 2000; Refsgaard et al. 2000). Second, certain FFAs can be unstable and  
15 they also have a tendency to bind non-specifically to proteins (Kodicek and Worden  
16 1945; Galbraith et al. 1971; Lacey and Lord 1981; Boyaval et al. 1995; Petschow et  
17 al. 1996; Guil-Guerrero et al. 2001). Finally, there may be a perceived lack of  
18 patentable intellectual property (IP) because FFAs are found so ubiquitously. As  
19 regards taste, a possible solution is to deliver the FFAs in the form of lipids together  
20 with a lipolytic enzyme. Such a combination, where the enzyme cleaves antibacterial  
21 FFAs from the lipid source, can be used to increase the *in situ* abundance of FFAs,  
22 such as inside an animal's gut (Dierick et al. 2002). This form of administration also  
23 subverts the problem of FFA instability because the FFAs will be delivered as stable  
24 lipids (e.g. triglycerides). If the problem of taste can be solved, one of the most  
25 lucrative areas for development could be in controlling the growth of pathogens or

1 spoilage bacteria in food (Wang and Johnson 1992; Ouattara et al. 1997; Shin et al.  
2 2007; Desbois et al. 2008, 2009). Monoglycerides, which tend not to have an  
3 unsavoury taste, are already used in food preservation (Shibasaki and Kato 1978).  
4 One of the most exciting potential applications for antibacterial FFAs is their use in  
5 topical medicine for the prevention and treatment of bacterial diseases. With respect  
6 to IP opportunities, new IP could be generated by exploring interactions between  
7 FFAs and conventional antibiotics or other agents with the aim of identifying  
8 synergistic combinations, as investigations to this end have been reported only  
9 sparsely (Shibasaki and Kato 1978; Wille and Kydonieus 2003; Drake et al. 2008).  
10 Combination therapies, where multiple antibacterial agents are given together, are  
11 desirable as they can reduce the opportunity for bacterial resistance to emerge (Zhao  
12 and Drlica 2001). Treatments containing a FFA component will further reduce the  
13 opportunity for resistance to emerge due to the FFA's non-specific mode of action.  
14 Additionally, studies of chemically altered FFAs engineered for more desirable 'drug-  
15 like' characteristics may prove to be another fruitful avenue to success.  
16  
17 Ultimately, the choice of FFAs is application-dependent and will differ according to  
18 the requirements of the process and the bacteria to be targeted. Specific mixtures  
19 could be produced that are optimised for each application and finely tuned for potency  
20 and spectrum. These could be mixed with solvents, stabilisers or other compounds to  
21 further enhance activity.

22

## 23 **Acknowledgements**

24

1 APD wishes to acknowledge financial support from the Wellcome Trust through the  
2 Value in People (VIP) award scheme. The authors thank Dr Rob Hagan (University  
3 of St Andrews) for his helpful comments on this manuscript.

4

## 5 **References**

6

7 Adolph S, Bach S, Blondel M, Cueff A, Moreau M, Pohnert G, Poulet SA, Wichard  
8 T, Zuccaro A (2004) Cytotoxicity of diatom-derived oxylipins in organisms belonging  
9 to different phyla. *J Exp Biol* 207: 2935-2946.

10

11 Alamsjah MA, Hirao S, Ishibashi F, Oda T, Fujita Y (2008) Algicidal activity of  
12 polyunsaturated fatty acids derived from *Ulva fasciata* and *U. pertusa* (Ulvaceae,  
13 Chlorophyta) on phytoplankton *J Appl Phycol* 20: 713-720.

14

15 Arzul G, Gentien P, Bodennec G, Toularastel F, Youenou A, Crassous MP (1995)  
16 Comparison of toxic effects in *Gymnodinium cf. nagasakiense* polyunsaturated fatty  
17 acids. In: Lassus P, Arzul G, Erard E, Genien P, Marcaillou C (eds) Harmful marine  
18 algal blooms. Intercept Ltd., Andover, pp 257-287.

19

20 Beck V, Jabůrek M, Demina T, Rupprecht A, Porter RK, Ježek P, Pohl EE (2007)  
21 Polyunsaturated fatty acids activate human uncoupling proteins 1 and 2 in planar lipid  
22 bilayers. *FASEB J* 21: 1137-1144.

23

1 Benkendorff K, Davis AR, Rogers CN, Bremner JB (2005) Free fatty acids and  
2 sterols in the benthic spawn of aquatic molluscs, and their associated antimicrobial  
3 properties. *J Exp Mar Biol Ecol* 316: 29-44.  
4  
5 Bergsson G, Arnfinnsson J, Karlsson SM, Steingrímsson Ó, Thormar H (1998) In  
6 vitro inactivation of *Chlamydia trachomatis* by fatty acids and monoglycerides.  
7 *Antimicrob Agents Chemother* 42: 2290-2294.  
8  
9 Bergsson G, Arnfinnsson J, Steingrímsson Ó, Thormar H (2001) Killing of Gram-  
10 positive cocci by fatty acids and monoglycerides. *APMIS* 109: 670-678.  
11  
12 Bergsson G, Steingrímsson Ó, Thormar H (1999) In vitro susceptibilities of *Neisseria*  
13 *gonorrhoeae* to fatty acids and monoglycerides. *Antimicrob Agents Chemother* 43:  
14 2790-2792.  
15  
16 Borowitzka MA (1988) Fats, oils and hydrocarbons. In: Borowitzka MA, Borowitzka  
17 LJ (eds) *Micro-algal biotechnology*. Cambridge University Press, Cambridge, pp 257-  
18 287.  
19  
20 Borst P, Loos JA, Christ EJ, Slater EC (1962) Uncoupling activity of long-chain fatty  
21 acids. *Biochim Biophys Acta* 62: 509-518.  
22  
23 Boyaval P, Corre C, Dupuis C, Roussel E (1995) Effects of free fatty acids on  
24 propionic acid bacteria. *Lait* 75: 17-29.  
25

1 Carson DD, Daneo-Moore L (1980) Effects of fatty acids on lysis of *Streptococcus*  
2 *faecalis*. J Bacteriol 141: 1123-1126.  
3  
4 Chamberlain NR, Mehrtens BG, Xiong Z, Kapral FA, Boardman JL, Rearick JI  
5 (1991) Correlation of carotenoid production, decreased membrane fluidity, and  
6 resistance to oleic acid killing in *Staphylococcus aureus* 18Z. Infect Immun 59: 4332-  
7 4337.  
8  
9 Chisti Y (2008) Response to Reijnders: do biofuels from microalgae beat biofuels  
10 from terrestrial plants? Trend Biotechnol 26: 351-352.  
11  
12 Clarke SR, Mohamed R, Bian L, Routh AF, Kokai-Kun JF, Mond JJ, Tarkowski A,  
13 Foster SJ (2007) The *Staphylococcus aureus* surface protein isdA mediates resistance  
14 to innate defenses of human skin. Cell Host & Microbe 1: 1-14.  
15  
16 Clinical and Laboratory Standards Institute (2000) Methods for dilution antimicrobial  
17 susceptibility tests for bacteria that grow aerobically; approved standard M7-A5. 5<sup>th</sup>  
18 edition. Wayne, PA.  
19  
20 Curtis RF, Coxon DT, Levett G (1974) Toxicity of fatty acids in assays for  
21 mycotoxins using the brine shrimp (*Artemia salina*). Food Cosmet Toxicol 12: 233-  
22 235.  
23

1 Cutignano A, d'Ippolito G, Romano G, Lamari N, Cimino G, Febbraio F, Nucci R,  
2 Fontana A (2006) Chloroplastic glycolipids fuel aldehyde biosynthesis in the marine  
3 diatom *Thalassiosira rotula*. ChemBioChem 7: 450-456.  
4  
5 Cybulski LE, Albanesi D, Mansilla MC, Altabe S, Aguilar PS, de Mendoza D (2002)  
6 Mechanism of membrane fluidity optimization: isothermal control of the *Bacillus*  
7 *subtilis* acyl-lipid desaturase. Mol Microbiol 45: 1379-1388.  
8  
9 Davies DG, Marques CNH (2009) A fatty acid messenger is responsible for inducing  
10 dispersion in microbial biofilms. J Bacteriol 191: 1393-1403.  
11  
12 de la Noue J, De Pauw N (1988) The potential of microalgal biotechnology: a review  
13 of production and uses of microalgae. Biotech Adv 6: 725-770.  
14  
15 Desbois AP, Lebl T, Yan L, Smith VJ (2008) Isolation and structural characterisation  
16 of two antibacterial free fatty acids from the marine diatom, *Phaeodactylum*  
17 *tricornutum*. Appl Microbiol Biotechnol 81: 755-764.  
18  
19 Desbois AP, Mearns-Spragg A, Smith VJ (2009) A fatty acid from the diatom  
20 *Phaeodactylum tricornutum* is antibacterial against diverse bacteria including multi-  
21 resistant *Staphylococcus aureus* (MRSA). Mar Biotechnol 11: 45-52.  
22  
23 Dibner JJ, Richards JD (2005) Antibiotic growth promoters in agriculture: history and  
24 mode of action. Poultry Sci 84: 634-643.  
25

1 Dierick NA, Decuypere JA, Molly K, Van Beek E, Vanderbeke E (2002) The  
2 combined use of triacylglycerides (TAGs) containing medium chain fatty acids  
3 (MCFAs) and exogenous lipolytic enzymes as an alternative to nutritional antibiotics  
4 in piglet nutrition. II. In vivo release of MCFAs in gastric cannulated and slaughtered  
5 piglets by endogenous and exogenous lipases; effects on the luminal gut flora and  
6 growth performance. *Livest Prod Sci* 76: 1-16.

7

8 Dohme F, Machmüller A, Wasserfallen A, Kreuzer M (2001) Ruminant  
9 methanogenesis as influenced by individual fatty acids supplemented to complete  
10 ruminant diets. *Lett Appl Microbiol* 32: 47-51.

11

12 Drake DR, Brogden KA, Dawson DV, Wertz PW (2008) Antimicrobial lipids at the  
13 skin surface. *J Lipid Res* 49: 4-11.

14

15 European Union (2005) On additives for use in animal nutrition. Commission  
16 Regulation (EC) No 378/2005 of 4 March 2005.

17

18 Feldlaufer MF, Knox DA, Lusby WR, Shimanuki H (1993) Antimicrobial activity of  
19 fatty acids against *Bacillus larvae*, the causative agent of American foulbrood disease.  
20 *Apidologie* 24: 95-99.

21

22 Finstad HS, Kolset SO, Holme JA, Wiger R, Farrants AKO, Blomhoff R, Drevon CA  
23 (1994) Effect of n-3 and n-6 fatty-acids on proliferation and differentiation of  
24 promyelocytic leukemic HL-60 cells. *Blood* 84: 3799-3809.

25

1 Fluhr JW, Kao J, Jain M, Ahn SK, Feingold KR, Elias PM (2001) Generation of free  
2 fatty acids from phospholipids regulates stratum corneum acidification and integrity. J  
3 Invest Dermatol 117: 44-51.

4

5 Fu M, Koulman A, van Rijssel M, Lützen A, de Boer MK, Tyl MR, Liebezeit G  
6 (2004) Chemical characterisation of three haemolytic compounds from the microalgal  
7 species *Fibrocapsa japonica* (Raphidophyceae). Toxicon 43: 355-363.

8

9 Galbraith H, Miller TB (1973a) Physiological effects of long chain fatty acids on  
10 bacterial cells and their protoplasts. J Appl Bacteriol 36: 647-658.

11

12 Galbraith H, Miller TB (1973b) Effect of long chain fatty acids on bacterial  
13 respiration and amino acid uptake. J Appl Bacteriol 36: 659-675.

14

15 Galbraith H, Miller TB (1973c) Effect of metal cations and pH on the antibacterial  
16 activity and uptake of long chain fatty acids. J Appl Bacteriol 36: 635-646.

17

18 Galbraith H, Miller TB, Paton AM, Thompson JK (1971) Antibacterial activity of  
19 long chain fatty acids and the reversal with calcium, magnesium, ergocalciferol and  
20 cholesterol. J Appl Bacteriol 34: 803-813.

21

22 Georgel P, Crozat K, Lauth X, Makrantonaki E, Seltmann H, Sovath S, Hoebe K, Du  
23 X, Rutschmann S, Jiang Z, Bigby T, Nizet V, Zouboulis CC, Beutler B (2005) A toll-  
24 like receptor 2-responsive lipid effector pathway protects mammals against skin  
25 infections with Gram-positive bacteria. Infect Immun 73: 4512-4521.

1

2 Greenway DLA, Dyke KGH (1979) Mechanism of the inhibitory action of linoleic  
3 acid on the growth of *Staphylococcus aureus*. J Gen Microbiol 115: 233-245.

4

5 Guil-Guerrero JL, Giménez- Giménez A, Robles-Medina A, del Mar Reboloso-  
6 Fuentes M, Belarbi E-H, Esteban-Cerdán L, Molina-Grima E. (2001) Hexane reduces  
7 peroxidation of fatty acids during storage. Eur J Lipid Sci Technol 103: 271-278.

8

9 Gutteridge JMC, Lamport P, Dormandy TL (1974) Autoxidation as a cause of  
10 antibacterial activity in unsaturated fatty acids. J Med Microbiol 7: 387-389.

11

12 Hamel FG (2009) Preliminary report: inhibition of cellular proteasome activity by free  
13 fatty acids. Metabolism 58: 1047-1049.

14

15 Harada K-I, Suomalainen M, Uchida H, Masui H, Ohmura K, Kiviranta J, Niku-  
16 Paavola M-L, Ikemoto T (2000) Insecticidal compounds against mosquito larvae from  
17 *Oscillatoria agardhii* strain 27. Environ Toxicol 15: 114-119.

18

19 Hazell SL, Graham DY (1990) Unsaturated fatty acids and the viability of  
20 *Helicobacter (Campylobacter) pylori*. J Clin Microbiol 28: 1060-1061.

21

22 Heczko PB, Lütticken R, Hryniewicz W, Neugebauer M, Pulverer G (1979)  
23 Susceptibility of *Staphylococcus aureus* and group A, B, C, and G streptococci to free  
24 fatty acids. J Clin Microbiol 9: 333-335.

25

1 Hemsworth GR, Kochan I (1978) Secretion of antimycobacterial fatty acids by  
2 normal and activated macrophages. *Infect Immun* 19: 170-177.  
3  
4 Hilmarsson H, Larusson LV, Thormar H (2006) Virucidal effect of lipids on visna  
5 virus, a lentivirus related to HIV. *Arch Virol* 151: 1217-1224.  
6  
7 Hogan JS, Pankey JW, Duthie AH (1987) Growth inhibition of mastitis pathogens by  
8 long-chain fatty acids. *J Dairy Sci* 70: 927-934.  
9  
10 Hornitzky M (2003) Fatty acids – an alternative control strategy for honey bee  
11 diseases. A report for the Rural Industries Research and Development Corporation.  
12 Publication no. 03/028. Rural Industries Research and Development Corporation,  
13 Barton, Australia.  
14  
15 Ikawa M, Sasner JJ, Haney JF (1997) Inhibition of *Chlorella* growth by degradation  
16 and related products of linoleic and linolenic acids and the possible significance of  
17 polyunsaturated fatty acids in phytoplankton ecology. *Hydrobiologia* 356: 143-148.  
18  
19 Isaacs CE, Litov RE, Thormar H (1995) Antimicrobial activity of lipids added to  
20 human milk, infant formula, and bovine milk. *J Nutr Biochem* 6: 362-366.  
21  
22 Jensen RA, Morse DE, Petty RL, Hooker N (1990) Artificial induction of larval  
23 metamorphosis by free fatty acids. *Mar Ecol Prog Ser* 67: 55-71.  
24

1 Jüttner F (2001) Liberation of 5,8,11,14,17-eicosapentaenoic acid and other  
2 polyunsaturated fatty acids from lipids as a grazer defense reaction in epilithic diatom  
3 biofilms. *J Phycol* 37: 744-755.  
4

5 Kabara JJ (1979) Toxicological, bacteriocidal and fungicidal properties of fatty acids  
6 and some derivatives. *J Am Oil Chem Soc* 56: 760A-767A.  
7

8 Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP (1972) Fatty acids and  
9 derivatives as antimicrobial agents. *Antimicrob Agents Chemother* 2: 23-28.  
10

11 Kabara JJ, Vrable R, Lie Ken Jie MSF (1977) Antimicrobial lipids: natural and  
12 synthetic fatty acids and monoglycerides. *Lipids* 12: 753-759.  
13

14 Kakisawa H, Asari F, Kusumi T, Toma T, Sakurai T, Oohusa T, Hara Y, Chihara M  
15 (1988) An allelopathic fatty acid from the brown alga *Cladosiphon okamuranus*.  
16 *Phytochemistry* 27: 731-735.  
17

18 Kankaanpää P, Yang B, Kallio H, Isolauri E, Salminen S (2004) Effects of  
19 polyunsaturated fatty acids in growth medium on lipid composition and on  
20 physicochemical surface properties of lactobacilli. *Appl Environ Microbiol* 70: 129-  
21 136.  
22

23 Kenny JG, Ward D, Josefsson E, Jonsson I-M, Hinds J, Rees HH, Lindsay JA,  
24 Tarkowski A, Horsburgh MJ (2009) The *Staphylococcus aureus* response to

1 unsaturated long chain free fatty acids: survival mechanisms and virulence  
2 implications. PLoS One 4: e4344.  
3  
4 Khan WA, Blobe GC, Hannun YA (1995) Arachidonic acid and free fatty acids as  
5 second messengers and the role of protein kinase C. Cell Signal 7: 171-184.  
6  
7 Knapp HR, Melly MA (1986) Bactericidal effects of polyunsaturated fatty acids. J  
8 Infect Dis 154: 84-94.  
9  
10 Ko HL, Heczko PB, Pulverer G (1978) Differential susceptibility of *Propionibacterium*  
11 *acnes*, *P. granulosum* and *P. avidum* to free fatty acids. J Invest Dermatol 71: 363-  
12 365.  
13  
14 Kodicek E, Worden AN (1945) The effect of unsaturated fatty acids on *Lactobacillus*  
15 *helveticus* and other Gram-positive micro-organisms. Biochem J 39: 78-85.  
16  
17 Kristmundsdóttir T, Árnadóttir SG, Bergsson G, Thormar H (1999) Development and  
18 evaluation of microbicidal hydrogels containing monoglyceride as the active  
19 ingredient. J Pharm Sci 88: 1011-1015.  
20  
21 Küpper FC, Gaquerel E, Bonener E-M, Morath S, Salaün J-P, Potin P (2006) Early  
22 events in the perception of lipopolysaccharides in the brown alga *Laminaria digitata*  
23 include an oxidative burst and activation of fatty acid oxidation cascades. J Exp Bot  
24 57: 1991-1999.  
25

1 Kurihara H, Goto Y, Aida M, Hosokawa M, Takahashi K (1999) Antibacterial  
2 activity against cariogenic bacteria and the inhibition of insoluble glucan production  
3 by free fatty acids obtained from dried *Gloiopeltis furcata*. Fish Sci 65: 129-132.  
4

5 Lacey RW, Lord VL (1981) Sensitivity of staphylococci to fatty acids: novel  
6 inactivation of linolenic acid by serum. J Med Microbiol 14: 41-49.  
7

8 Liaw S-J, Lai H-C, Wang W-B (2004) Modulation of swarming and virulence by fatty  
9 acids through the rsbA protein in *Proteus mirabilis*. Infect Immun 72: 6836-6845.  
10

11 Lu Z-H, Mu Y-M, Wang B-A, Li X-L, Lu J-M, Li J-Y, Pan C-Y, Yanase T, Nawata H  
12 (2003) Saturated free fatty acids, palmitic acid and stearic acid, induce apoptosis by  
13 stimulation of ceramide generation in rat testicular Leydig cell. Biochem Biophys Res  
14 Commun 303: 1002-1007.  
15

16 Lukowski G, Lindequist U, Mundt S, Kramer A, Jülich W-D (2008) Inhibition of  
17 dermal MRSA colonisation by microalgal micro- and nanoparticles. Skin Pharmacol  
18 Physiol 21: 98-105.  
19

20 Marshall J-A, Nichols PD, Hamilton B, Lewis RJ, Hallegraef GM (2003)  
21 Ichthyotoxicity of *Chattonella marina* (Raphidophyceae) to damselfish  
22 (*Acanthochromis polycanthus*): the synergistic role of reactive oxygen species and  
23 free fatty acids. Harmful Algae 2: 273-281.  
24

1 McGaw LJ, Jäger AK, van Staden J (2002) Antibacterial effects of fatty acids and  
2 related compounds from plants. S Afr J Bot 68: 417-423.  
3  
4 McGrattan CJ, Sullivan, JD Jr, Ikawa M (1976) Inhibition of *Chlorella*  
5 (Chlorophyceae) growth by fatty acids, using the paper disc method. J Phycol 12:  
6 129-131.  
7  
8 Miller RD, Brown KE, Morse SA (1977) Inhibitory action of fatty acids on the  
9 growth of *Neisseria gonorrhoeae*. Infect Immun 17: 303-312.  
10  
11 Mitchell P (1961) Coupling of phosphorylation to electron and hydrogen transfer by a  
12 chemi-osmotic type of mechanism. Nature 191: 144-148.  
13  
14 Murakami M, Makabe K, Yamaguchi K, Konosu S (1989) Cytotoxic polyunsaturated  
15 fatty acid from *Pediastrum*. Phytochemistry 28: 625-626.  
16  
17 Nakatsuji T, Kao MC, Fang J-Y, Zouboulis CC, Zhang L, Gallo RL, Huang C-M  
18 (2009) Antimicrobial property of lauric acid against *Propionibacterium acnes*: its  
19 therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol 129: 2480-  
20 2488.  
21  
22 Nair MKM, Joy J, Vasudevan P, Hinckley L, Hoagland TA, Venkitanarayanan KS  
23 (2005) Antibacterial effect of caprylic acid and monocaprylin on major bacterial  
24 mastitis pathogens. J Dairy Sci 88: 3488-3495.  
25

1 Neyts J, Kristmundsdóttir T, De Clercq E, Thormar H (2000) Hydrogels containing  
2 monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice:  
3 impact on the search for vaginal microbicides. J Med Virol 61: 107-110.  
4

5 Osawa K, Miyazaki K, Shimura S, Okuda J, Matsumoto M, Ooshima T (2001)  
6 Identification of cariostatic substances in the cacao bean husk: their anti-  
7 glucosyltransferase and antibacterial activities. J Dent Res 80: 2000-2004.  
8

9 Ouattara B, Simard RE, Holley RA, Piette GJ-P, Bégin A (1997) Antibacterial  
10 activity of selected fatty acids and essential oils against six meat spoilage organisms.  
11 Int J Food Microbiol 37: 155-162.  
12

13 Pawlik JR (1986) Chemical induction of larval settlement and metamorphosis in the  
14 reef-building tube worm *Phragmatopoma californica* (Sabellariidae: Polychaeta). Mar  
15 Biol 91: 59-68.  
16

17 Peters JS, Chin C-K (2003) Inhibition of photosynthetic electron transport by  
18 palmitoleic acid is partially correlated to loss of thylakoid membrane proteins. Plant  
19 Physiol Biochem 41: 117-124.  
20

21 Petschow BW, Batema RP, Ford LL (1996) Susceptibility of *Helicobacter pylori* to  
22 bactericidal properties of medium-chain monoglycerides and free fatty acids.  
23 Antimicrob Agents Chemother 40: 302-306.  
24

1 Refsgaard HHF, Brockhoff PMB, Jensen B (2000) Free polyunsaturated fatty acids  
2 cause taste deterioration of salmon during frozen storage. J Agric Food Chem 48:  
3 3280-3285.  
4  
5 Reinikainen M, Meriluoto JAO, Spoo L, Harada K-I (2001) The toxicities of a  
6 polyunsaturated fatty acid and a microcystin to *Daphnia magna*. Environ Toxicol 16:  
7 444-448.  
8  
9 Rickrode TE (1986) Identification and antibiotic activity of fatty acids in dermal  
10 secretions of *Plethodon cinereus*. Am Midl Nat 115: 198-200.  
11  
12 Rohrer L, Winterhalter KH, Eckert J, Köhler P (1986) Killing of *Giardia lamblia* by  
13 human milk is mediated by unsaturated fatty acids. Antimicrob Agents Chemother 30:  
14 254-257.  
15  
16 Ruzin A, Novick RP (2000) Equivalence of lauric acid and glycerol monolaurate as  
17 inhibitors of signal transduction in *Staphylococcus aureus*. J Bacteriol 182: 2668-  
18 2671.  
19  
20 Saito H, Tomioka H, Yoneyama T (1984) Growth of group IV mycobacteria on  
21 medium containing various saturated and unsaturated fatty acids. Antimicrob Agents  
22 Chemother 26: 164-169.  
23

1 Sado-Kamdem SL, Vannini L, Guerzoni ME (2009) Effect of  $\alpha$ -linolenic, capric and  
2 lauric acid on the fatty acid biosynthesis in *Staphylococcus aureus*. Int J Food  
3 Microbiol 129: 288-294.  
4  
5 Schönfeld P, Wojtczak L (2008) Fatty acids as modulators of the cellular production  
6 of reactive oxygen species. Free Radic Biol Med 45: 231-241.  
7  
8 Sellem F, Pesando D, Bodenec G, El Abed A, Girard J-P (2000) Toxic effects of  
9 *Gymnodinium cf. mikimotoi* unsaturated fatty acids to gametes and embryos of the sea  
10 urchin *Paracentrotus lividus*. Wat Res 34: 550-556.  
11  
12 Shalita AR (1974) Genesis of free fatty acids. J Invest Dermatol 62: 332-335.  
13  
14 Sheu CW, Freese E (1972) Effects of fatty acids on growth and envelope proteins of  
15 *Bacillus subtilis*. J Bacteriol 111: 516-524.  
16  
17 Shibasaki I, Kato N (1978) Combined effects on antibacterial activity of fatty acids  
18 and their esters against Gram-negative bacteria. In: Kabara JJ (ed) Symposium on the  
19 pharmacological effect of lipids. The American Oil Chemists' Society, Champaign,  
20 pp 15-24.  
21  
22 Shin SY, Bajpai, VK, Kim HR, Kang SC (2007) Antibacterial activity of  
23 eicosapentaenoic acid (EPA) against foodborne and food spoilage microorganisms  
24 LWT 40: 1515-1519.  
25

1 Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M,  
2 Loeb M, McGeer A, Bryce E, Matlow A (2007) Mupirocin-resistant, methicillin-  
3 resistant *Staphylococcus aureus* strains in Canadian hospitals. *Antimicrob Agents*  
4 *Chemother* 51: 3880-3886.

5

6 Skřivanová E, Molatová Z, Marounek M (2008) Effects of caprylic acid and  
7 triacylglycerols of both caprylic and capric acid in rabbits experimentally infected  
8 with enteropathogenic *Escherichia coli* O103. *Vet Microbiol* 126: 372-376.

9

10 Smith DL, Harris AD, Johnson JA, Silbergeld EK, Morris JG Jr. (2002) Animal  
11 antibiotic use has an early but important impact on the emergence of antibiotic  
12 resistance in human commensal bacteria. *Proc Natl Acad Sci USA* 99: 6434-6439.

13

14 Speert DP, Wannamaker LW, Gray ED, Clawson CC (1979) Bactericidal effect of  
15 oleic acid on group A streptococci: mechanism of action. *Infect Immun* 26: 1202-  
16 1210.

17

18 Stenz L, François P, Fischer A, Huyghe A, Tangomo M, Hernandez D, Cassat J,  
19 Linder P, Schrenzel J (2008) Impact of oleic acid (*cis*-9-octadecenoic acid) on  
20 bacterial viability and biofilm production in *Staphylococcus aureus*. *FEMS Microbiol*  
21 *Lett* 287: 149-155.

22

23 Stephan A, Steinhart H (2000) Bitter taste of unsaturated free fatty acids in emulsions:  
24 contribution to the off-flavour of soybean lecithins. *Eur Food Res Technol* 212: 17-  
25 25.

1

2 Stulnig TM, Huber J, Leitinger N, Imre E-M, Angelisová, Nowotny P, Waldhäusl W  
3 (2001) Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts  
4 by altering raft lipid composition. *J Biol Chem* 276: 37335-37340.

5

6 Sun CQ, O'Connor CJ, Robertson AM (2003) Antibacterial actions of fatty acids and  
7 monoglycerides against *Helicobacter pylori*. *FEMS Immunol Med Microbiol* 36: 9-  
8 17.

9

10 Takigawa H, Nakagawa H, Kuzukawa M, Mori H, Imokawa G (2005) Deficient  
11 production of hexadecenoic acid in the skin is associated in part with the vulnerability  
12 of atopic dermatitis patients to colonisation by *Staphylococcus aureus*. *Dermatology*  
13 211: 240-248.

14

15 Thompson L, Cockayne A, Spiller RC (1994) Inhibitory effect of polyunsaturated  
16 fatty acids on the growth of *Helicobacter pylori*: a possible explanation of the effect  
17 of diet on peptic ulceration. *Gut* 35: 1557-1561.

18

19 Thormar H, Bergsson G, Gunnarsson E, Georgsson G, Witvrouw M, Steingrímsson  
20 Ó, De Clercq E, Kristmundsdóttir T (1999) Hydrogels containing monocaprin have  
21 potent microbicidal activities against sexually transmitted viruses and bacteria in  
22 vitro. *Sex Transm Inf* 75: 181-185.

23

1 Thormar H, Hilmarsson H (2007) The role of microbicidal lipids in host defense  
2 against pathogens and their potential as therapeutic agents. *Chem Phys Lipids* 150: 1-  
3 11.

4

5 Thormar H, Hilmarsson H, Bergsson G (2006) Stable concentrated emulsions of the  
6 1-monoglyceride of capric acid (moncaprin) with microbicidal activities against the  
7 food-borne bacteria *Campylobacter jejuni*, *Salmonella* spp., and *Escherichia coli*.  
8 *Appl Environ Microbiol* 72: 522-526.

9

10 Thormar H, Isaacs CE, Brown HR, Barshatzky MR, Pessolano T (1987) Inactivation  
11 of enveloped viruses and killing of cells by fatty acids and monoglycerides.  
12 *Antimicrob Agents Chemother* 31: 27–31.

13

14 Tsuchido T, Hiraoka T, Takano M, Shibasaki I (1985) Involvement of autolysin in  
15 cellular lysis of *Bacillus subtilis* induced by short- and medium-chain fatty acids. *J*  
16 *Bacteriol* 162: 42-46.

17

18 Ungerfeld EM, Rust SR, Burnett RJ, Yokoyama MT, Wang JK (2005) Effects of two  
19 lipids on in vitro ruminal methane production. *Animal Feed Sci Technol* 119: 179-  
20 185.

21

22 U.S. Food and Drug Administration (1997) Substances affirmed as generally  
23 recognized as safe: menhaden oil. *Federal Register* 62: 30751-30757.

24

1 van Rijen M, Bonten M, Wenzel R, Kluytmans J (2008) Mupirocin ointment for  
2 preventing *Staphylococcus aureus* infections in nasal carriers. Cochrane Database  
3 Syst Rev 4. doi: 10.1002/14651858.CD006216.pub2 (accessed 18 May 2009).  
4  
5 Wang L-L, Johnson EA (1992) Inhibition of *Listeria monocytogenes* by fatty acids  
6 and monoglycerides. Appl Environ Microbiol 58: 624–629.  
7  
8 Weber H (2002) Fatty acid-derived signals in plants. Trend Plant Sci 7: 217-224.  
9  
10 Wichard T, Gerecht A, Boersma M, Poulet SA, Wiltshire K, Pohnert G (2007) Lipid  
11 and fatty acid composition of diatoms revisited: rapid wound-activated change of food  
12 quality parameters influences herbivorous copepod reproductive success.  
13 ChemBioChem 8: 1146-1153.  
14  
15 Więckowski MR, Wojtczak L (1998) Fatty acid-induced uncoupling of oxidative  
16 phosphorylation is partly due to opening of the mitochondrial permeability transition  
17 pore. FEBS Lett 423: 339-342.  
18  
19 Wille JJ, Kydonieus A (2003) Palmitoleic acid isomer (C16:1 $\Delta$ 6) in human skin  
20 sebum is effective against Gram-positive bacteria. Skin Pharmacol Appl Skin Physiol  
21 16: 176-187.  
22  
23 Willett NP, Morse GE (1966) Long-chain fatty acid inhibition of growth of  
24 *Streptococcus agalactiae* in a chemically defined medium. J Bacteriol 91: 2245-2250.  
25

1 Wojtczak L, Więckowski MR (1999) The mechanisms of fatty acid-induced proton  
2 permeability of the inner mitochondrial membrane. *J Bioenerg Biomembr* 31: 447-  
3 455.

4

5 Won S-R, Hong M-J, Kim Y-M, Li CY, Kim J-W, Rhee H-I (2007) Oleic acid: an  
6 efficient inhibitor of glucosyltransferase. *FEBS Lett* 581: 4999-5002.

7

8 Wu J-T, Chiang Y-R, Huang W-Y, Jane W-N (2006) Cytotoxic effects of free fatty  
9 acids on phytoplankton algae and cyanobacteria. *Aquat Toxicol* 80: 338-345.

10

11 Xiong Z, Kapral FA (1992) Carotenoid pigment levels in *Staphylococcus aureus* and  
12 sensitivity to oleic acid. *J Med Microbiol* 37: 192-194.

13

14 Yang D, Pornpattananankul D, Nakatsuji T, Chan M, Carson D, Huang C-M, Zheng  
15 L (2009) The antimicrobial activity of liposomal lauric acids against  
16 *Propionibacterium acnes*. *Biomaterials* 30: 6035-6040.

17

18 Yff BTS, Lindsey KL, Taylor MB, Erasmus DG, Jäger AK (2002) The  
19 pharmacological screening of *Pentanisia prunelloides* and the isolation of the  
20 antibacterial compound palmitic acid. *J Ethnopharmacol* 79: 101-107.

21

22 Zhao X, Drlica K (2001) Restricting the selection of antibiotic-resistant mutants: a  
23 general strategy derived from fluoroquinolone studies. *Clin Infect Dis* 33: Suppl 3,  
24 S147-56.

25

- 1 Zheng CJ, Yoo JS, Lee TG, Cho HY, Kim YH, Kim WG (2005) Fatty acid synthesis
- 2 is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett 579: 5157-
- 3 5162.

1 **Figure legends**

2

3 **Figure 1.** Structure of free fatty acids (FFAs). (A) The saturated FFA, capric acid  
4 (C10:0), which has 10 carbon atoms in the carbon chain. The carbon chain length can  
5 vary but at one end is the carboxyl group ( $-\text{COOH}$ ) while at the other end is a methyl  
6 group ( $-\text{CH}_3$ ). The carboxyl group is hydrophilic and ionised when solubilised in  
7 water whereas the carbon chain and terminal methyl group are hydrophobic, making  
8 the entire molecule amphipathic. (B) Unsaturated FFAs have one or more  $\text{C}=\text{C}$  double  
9 bonds in the carbon chain and, here, the fatty acid is methylated, as the carboxyl  
10 group has an additional  $-\text{CH}_2$ . This fatty acid is C10:2n-3 as there are 10 carbon  
11 atoms in the carbon chain, there are 2  $\text{C}=\text{C}$  bonds of which the first of these is located  
12 3 carbon-carbon bonds from the methyl end.

13

14 **Figure 2.** Space-filled representations of 8 free fatty acids (FFAs). Saturated FFAs  
15 (e.g. lauric and stearic acids) have a simple ‘straight-line’ structure. A *cis*-double bond  
16 causes a kink in the carbon chain (e.g. myristic and oleic acids). Additional *cis*-double  
17 bonds in the carbon chain cause further kinks (e.g. linoleic,  $\gamma$ -linolenic and  
18 eicosapentaenoic acids). However, *trans*-double bonds have little effect on the shape  
19 (e.g. elaidic acid) and these FFAs structurally tend to resemble saturated FFAs (e.g.  
20 stearic acid).

21

22 **Figure 3.** Schematic representation of possible cell targets and mechanisms of  
23 antibacterial activity of free fatty acids (FFAs). They may affect bacterial energy  
24 production by disrupting the electron transport chain and/or interfering with oxidative  
25 phosphorylation. FFAs can cause leakage of cell metabolites from the cell, complete

1 cell lysis and autolysis. Membrane and cytosolic enzymes, including those required  
2 for fatty acid biosynthesis, can be inhibited by FFAs. They can impair active nutrient  
3 uptake by acting directly on the transport protein or as an indirect result of the cell's  
4 inability to produce ATP. Peroxidation and auto-oxidation products of FFAs may also  
5 have deleterious effects on the bacterial cell and play a role in cell killing. For clarity,  
6 only the bacterial inner cell membrane is shown.

7







Fig. 1


Fig. 2




lauric acid  
(C12:0)




myristoleic acid  
(C14:1n5)



elaidic acid  
(C18:1n-9*t*)



eicosapentaenoic acid  
(C20:5n-3)




stearic acid  
(C18:0)



oleic acid  
(C18:1n-9)



linoleic acid  
(C18:2n-6)



$\gamma$ -linolenic acid  
(C18:3n-6)



**Disruption of electron transport chain by:**

- direct binding to electron carriers.
- insertion between carriers preventing their interaction.
- complete displacement of carriers from the membrane.
- preventing carrier interactions by reducing fluidity of the membrane.

**Interference with oxidative phosphorylation by:**

- preventing correct functioning of ATP synthase by direct binding or complete displacement from the membrane.
- reducing proton gradient/membrane potential by increasing membrane permeability to protons or FFAs dissociating a proton inside the cell and then returning to the extracellular space.




Fig. 3

**Table 1** – Selected bioactivities of various saturated and unsaturated FFAs. Bond positions, where reported, are all in *cis* orientation unless marked *t* for *trans*.

Activity	Fatty acid(s)	Reference
<i>Antimicrobial</i>		
Anti-algal	C8:0, C10:0, C12:0	McGrattan et al. (1976)
	C18:4n-3	Kakisawa et al. (1988)
	C18:1, C18:2, C18:4, C18:5, C20:4, C20:5, C22:6	Arzul et al. (1995)
	C18:2n-6, C18:3n-3	Ikawa et al. (1997)
	C16:0, C18:0, C18:1n-9, C18:2, C18:3n-3, C20:5n-3, C22:6n-3	Wu et al. (2006)
	C16:0, C16:1n-7, C16:1n-7 <i>t</i> , C16:4n-3, C18:0, C18:1n-9, C18:2n-6, C18:3n-3, C18:4n-3, C20:0, C20:1n-9, C20:4n-6, C20:5n-3, C22:0, C22:1n-9, C22:6n-3	Alamsjah et al. (2008)
Antibacterial (Gram-negative)	C20:4n-6	Knapp and Melly (1986)
	C10:0, C12:0	Bergsson et al. (1998)
	C10:0, C12:0, C14:0, C16:1	Bergsson et al. (1999)
	C15:0, C16:0, C17:0, C18:0, C18:1, C18:4, C20:4, C20:5, C22:0, C22:4, C22:5	Benkendorff et al. (2005)
Antibacterial (Gram-positive)	C8:0, C10:0, C12:0, C14:0, C16:0, C18:0, C18:1, C18:2, C18:3	Galbraith et al. (1971)
	C10:0, C12:0, C14:0, C14:1, C16:0, C16:1, C18:1, C18:2, C18:3	Kabara et al. (1972)
	C8:0, C9:0, C10:0, C11:0, C12:0, C13:0, C14:0, C14:1n-5, C16:1n-7, C16:1n-7 <i>t</i> , C18:2n-6, C18:3n-3, C18:3n-6, C20:1n-9, C20:3n-6, C20:3n-3, C20:4n-6, C22:2n-6, C22:3n-3, C20:4n-6, C22:6n-3	Feldlaufer et al. (1993)

	C16:1n-10	Wille and Kydonieus (2003)
	C15:0, C18:1, C18:4, C20:4, C20:5, C22:0, C22:4, C22:5	Benkendorff et al. (2005)
Anti-fungal	C10:0, C12:0	Bergsson et al. (2001)
	C10:0, C12:0, C14:0, C14:1, C16:1, C18:2	Kabara et al. (1972)
Anti-protozoan	C18:0, C18:1, C18:2, C18:3	Rohrer et al. (1986)
	C8:0, C10:0, C12:0	Dohme et al. (2001)
Antiviral	C8:0, C10:0, C12:0, C14:0, C16:1, C18:1, C18:2, C18:3, C20:4	Thormar et al. (1987)
	C10:0, C12:0, C14:0, C16:1, C18:1	Hilmarsson et al. (2006)
<i>Cytotoxic</i>		
Haemolytic (sheep erythrocytes)	C18:0, C18:1, C18:2, C18:3, C18:4, C18:5, C20:4, C20:5, C22:6	Arzul et al. (1995)
Haemolytic (human erythrocytes)	C20:4n-6, C20:5n-3	Fu et al. (2004)
Inhibits cell division (mammalian leukemic HL-60 cells)	C20:4n-6, C20:5n-3, C22:6n-3	Finstad et al. (1994)
Inhibits cell division (sea urchin eggs)	C18:4, C18:5, C20:5, C22:6	Sellem et al. (2000)
Inhibits development of fertilised echinoderm eggs	C16:4n-3	Murakami et al. (1989)
Inhibits photosynthesis	C16:1n-7	Peters and Chin (2003)
Reduces viability of rat Leydig cells	C16:0, C18:0	Lu et al. (2003)
<i>Toxic to whole organisms</i>		

Brine shrimp larvae	C8:0, C10:0, C12:0, C18:1, C18:2, C18:3, C20:4	Curtis et al. (1974)
<i>Daphnia</i> (Crustacean)	C18:3n-6	Reinikainen et al. (2001)
Fairy shrimp (Crustacean)	C20:5n-3	Jüttner (2001)
Fish	C20:5n-3	Marshall et al. (2003)
Mosquito larvae	C18:1, C18:2, C18:3n-6	Harada et al. (2000)
Tube worm (marine)	C20:4, C20:5	Pawlik (1986)
<i>Signalling</i>		
Increases expression of bacterial proteins for energy metabolism, cell wall and protein synthesis	C16:1n-6, C18:2n-6	Kenny et al. (2009)
Induces larval settlement and metamorphosis	C16:1, C18:2, C20:4, C20:5	Pawlik (1986); Jensen et al. (1990)
Inhibits bacterial attachment	C18:1n-9	Stenz et al. (2008)
Reduces expression of bacterial virulence factors: $\beta$ -lactamase and Toxic Shock Syndrome Toxin (TSST)	C12:0	Ruzin and Novick (2000)
Reduces expression of bacterial virulence factors: $\beta$ -lactamase and haemolysin	C16:1n-6	Clarke et al. (2007)
Reduces expression of bacterial virulence factors: haemolysin	C12:0, C14:0, C16:0, C18:0	Liaw et al. (2004)
Regulates bacterial swarming	C12:0, C14:0, C16:0, C18:0, C18:1	Liaw et al. (2004)
Regulates protein kinase C activation	C20:4n-6	Khan et al. (1995)

---